CStone Pharmaceuticals (HKSE:02616) EPS (Basic) : HK$-0.70 (TTM As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals EPS (Basic)?

CStone Pharmaceuticals's basic earnings per share (Basic EPS) for the six months ended in Jun. 2023 was HK$-0.19. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-0.70.

CStone Pharmaceuticals's EPS (Diluted) for the six months ended in Jun. 2023 was HK$-0.19. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-0.70.

CStone Pharmaceuticals's EPS without NRI for the six months ended in Jun. 2023 was HK$-0.19. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was -0.67.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

CStone Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for CStone Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals EPS (Basic) Chart

CStone Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-2.66

-1.39

-2.02

-0.86

-0.32

CStone Pharmaceuticals Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial									-1.20	-0.36	-0.51	-0.19	-

CStone Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

CStone Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-401.673	-	0)	/	1263.073
	=	-0.32

CStone Pharmaceuticals's Basic EPS for the quarter that ended in Jun. 2023 is calculated as

Basic EPS (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-228.847	-	0)	/	1251.793
	=	-0.18

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.70

CStone Pharmaceuticals (HKSE:02616) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

CStone Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

CStone Pharmaceuticals (HKSE:02616) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (HKSE:02616) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

CSPHF:USA PH4:Germany

Address

218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123

Website

https://www.cstonepharma.com

CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

CStone Pharmaceuticals (HKSE:02616) Headlines

No Headlines